Synthetica Pioneering Completes Series A Funding Round to Advance Oncolytic Bacterial Treatment for Solid Tumors
Wednesday, July 31, 2024
Shenzhen Synthetica Pioneering Co., Ltd. (Synthetica), a biotech startup focused on synthetic biology for creating novel bacterial therapeutics, has recently completed a Series A funding round. The investment was led by Boehringer Ingelheim Venture Fund and Temasek, with additional contributions from Lenovo Capital, Fosun Health Capital, and ATLATL Summer Fund. The funds will be used to expedite the clinical trials of Synthetica's oncolytic bacterial therapies.
Established in 2023 and based in Shenzhen, China, Synthetica specializes in genetic circuit engineering to precisely control genes and payloads for therapeutic purposes. The company is currently concentrating on developing oncolytic bacterial therapies for the treatment of solid tumors. With advanced synthetic biology techniques and a strong grasp of biological mechanisms, Synthetica aims to create innovative, safe, and minimally invasive treatments for cancer.
Synthetica’s CEO, Yingke He, expressed, “This funding represents a crucial development for our company as we advance cancer treatment. Our approach to synthetic biology and oncolytic bacteria provides new possibilities for targeted therapies. We appreciate the support from our technology partners and investors, and we are committed to making significant progress in cancer treatment to improve patients' lives worldwide.”
Dr. Mia Hu, Investment Director at Boehringer Ingelheim Venture Fund, noted, “Boehringer Ingelheim Venture Fund is dedicated to supporting innovative therapeutics that address significant patient needs. Oncolytic bacterial therapy is a strategic priority for us, and we are excited to back Synthetica. Their expertise in synthetic biology and the development of bacterial therapies is promising, and we are eager to see their impact on treating solid tumors and enhancing patient outcomes.”
Source: prnewswire.com
